IL165253A0 - Methods and compositions for the treatment of ischemic reperfusion - Google Patents

Methods and compositions for the treatment of ischemic reperfusion

Info

Publication number
IL165253A0
IL165253A0 IL16525303A IL16525303A IL165253A0 IL 165253 A0 IL165253 A0 IL 165253A0 IL 16525303 A IL16525303 A IL 16525303A IL 16525303 A IL16525303 A IL 16525303A IL 165253 A0 IL165253 A0 IL 165253A0
Authority
IL
Israel
Prior art keywords
compositions
treatment
methods
ischemic reperfusion
reperfusion
Prior art date
Application number
IL16525303A
Other languages
English (en)
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of IL165253A0 publication Critical patent/IL165253A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16525303A 2002-05-17 2003-05-16 Methods and compositions for the treatment of ischemic reperfusion IL165253A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38165302P 2002-05-17 2002-05-17
US40547802P 2002-08-23 2002-08-23
PCT/US2003/015469 WO2003097696A1 (en) 2002-05-17 2003-05-16 Methods and copositions for the treatment of ischemic reperfusion

Publications (1)

Publication Number Publication Date
IL165253A0 true IL165253A0 (en) 2005-12-18

Family

ID=29553542

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16525303A IL165253A0 (en) 2002-05-17 2003-05-16 Methods and compositions for the treatment of ischemic reperfusion

Country Status (13)

Country Link
US (1) US20040038891A1 (zh)
EP (1) EP1556413A4 (zh)
JP (1) JP2006502976A (zh)
KR (1) KR20050010006A (zh)
CN (1) CN1668645A (zh)
AU (1) AU2003234625A1 (zh)
BR (1) BR0310100A (zh)
CA (1) CA2485989A1 (zh)
IL (1) IL165253A0 (zh)
MX (1) MXPA04011227A (zh)
NZ (1) NZ537006A (zh)
PL (1) PL374126A1 (zh)
WO (1) WO2003097696A1 (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
AU2003254202A1 (en) * 2002-07-30 2004-02-16 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
WO2005011586A2 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR20110088574A (ko) 2004-02-04 2011-08-03 미쓰비시 타나베 파마 코퍼레이션 파라옥소나아제 함유 제제
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006107107A1 (ja) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
JP2012532919A (ja) 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療因子を含むｈｄｌおよび治療における使用
EP2525780B1 (en) 2010-01-19 2022-09-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CN103118683B (zh) 2010-06-30 2015-08-19 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
CA2807448A1 (en) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
CN103391786B (zh) * 2011-01-19 2016-06-22 辛辛那提大学 作为抗糖尿病肽的载脂蛋白a-iv
WO2012170633A1 (en) 2011-06-09 2012-12-13 Lifeline Scientific, Inc. Data record for organ transport and/or storage, comprising biomarker and events information
KR20140054115A (ko) 2011-08-25 2014-05-08 에프. 호프만-라 로슈 아게 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
BR112014017141A2 (pt) 2012-01-19 2019-09-24 Univ Cincinnati método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US20140278468A1 (en) 2013-03-15 2014-09-18 I.D. Therapeutics Llc Apparatus and method for optimizing treatment using medication compliance patterns and glucose sensor
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016057549A1 (en) 2014-10-06 2016-04-14 Aurasense Therapeutics, Llc Anti-tnf compounds
WO2016085986A1 (en) * 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
TW201822812A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療肥胖症的方法
CA3047175A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for mitigating heart disease
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
EP3600278B1 (en) * 2017-03-31 2021-01-27 Fundació Institut de Recerca de l'Hospital de la Santa creu i Sant Pau Statin for prevention/reduction of ischemia-related damage
AU2018375199B2 (en) 2017-12-01 2023-03-30 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
WO2022099574A1 (zh) * 2020-11-13 2022-05-19 兰州大学 哌唑嗪用于制备治疗和/或预防脑血管疾病药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0228458B2 (en) * 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
JPH02231708A (ja) * 1989-03-06 1990-09-13 Fujitsu Ltd 半導体装置の位置合わせマーク検出方法及び装置
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) * 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
EA199800279A1 (ru) * 1995-10-11 1999-04-29 Талариа Терапьютикс, Инк Липосомные композиции и способы их применения
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7208288B2 (en) * 2000-10-13 2007-04-24 Broderick Joseph P Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype
EP1425031B8 (en) * 2001-08-20 2008-09-03 CSL Behring AG Hdl for the treatment of stroke and other ischemic conditions

Also Published As

Publication number Publication date
EP1556413A4 (en) 2009-07-08
BR0310100A (pt) 2007-04-27
NZ537006A (en) 2008-01-31
WO2003097696A1 (en) 2003-11-27
CA2485989A1 (en) 2003-11-27
MXPA04011227A (es) 2005-01-25
PL374126A1 (en) 2005-10-03
JP2006502976A (ja) 2006-01-26
AU2003234625A1 (en) 2003-12-02
CN1668645A (zh) 2005-09-14
KR20050010006A (ko) 2005-01-26
US20040038891A1 (en) 2004-02-26
EP1556413A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
IL165253A0 (en) Methods and compositions for the treatment of ischemic reperfusion
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
EP1644021A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
AU2003239129A8 (en) Methods and compositions for dna manipulation
EP1696910A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
EP1720893A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF ARTHRITIS
EP1567183A4 (en) METHOD AND COMPOSITIONS FOR TREATING OTITIS MEDIA
AU2003297573A8 (en) Compositions and methods for treating transplants
GB0303609D0 (en) Novel therapeutic method and compositions
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
EP1575497A4 (en) NEW COMPOSITION AND METHOD FOR TREATING PSORIASIS
GB0324523D0 (en) Compositions and methods of treatment
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003275433A8 (en) Compositions and methods for treating pain
ZA200409350B (en) Methods and compositions for the treatment of ischemic reperfusion
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0303600D0 (en) Novel therapeutic method and compositions
EP1549761A4 (en) METHOD AND COMPOSITIONS FOR MODIFYING NUCLEAR SULFURES
AU2003245524A8 (en) Cryosurgery compositions and methods
EP1546326A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
GB0205826D0 (en) Therapeutic compositions and methods
GB0203528D0 (en) Process and composition
GB0211831D0 (en) Therapeutic methods and compositions